Moneycontrol
HomeNewsBusinessMarketsWill the 2020 meltdown mimic 2008? Possible, but there is a caveat
Trending Topics

Will the 2020 meltdown mimic 2008? Possible, but there is a caveat

History suggests that there could be a possibility of a further fall in the markets which could be even more severe compared to the one which we have seen in March.

April 16, 2020 / 09:53 IST
Story continues below Advertisement

Many are drawing parallels with the 2008 financial crisis which wiped out more than 50 percent of the benchmark value in a matter of months. The meltdown which we are witnessing in 2020 is a ‘health crisis’ which could well turn into a financial crisis as economies across the globe are virtually shut down.

The 2008 crash lasted around 300 days and the Nifty50 fell a total of 60 percent. But, the fall was not unidirectional, and the market fell in three steps. After each fall, the market saw a small (sharp) rebound only to fall lower in the next crash (refer chart).

Story continues below Advertisement

The current crash, as such, has seen only the first step of the crash, though the correction has been much sharper. Experts feel that another down move is possible; however, there is a caveat and that is if we develop a vaccine for COVID-19, it could fuel a risk-on sentiment in equity markets across the globe.

“The Nifty50 fell 38 percent from peak to bottom over a period of 66 days. Historically, most bear markets last for at least 3 months. As a result, depending on the extent of the lockdown in India and the rate of spread of COVID-19 across the world, the market may see further correction in the coming months,” IDFC MF said in a report.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show